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ABSTRACT 55 
Objectives 56 
Rapid and accurate sexually transmitted infection diagnosis can reduce onward transmission 57 
and improve treatment efficacy. We evaluated the accuracy of a 15-minute run-time 58 
recombinase polymerase amplification (RPA)-based prototype point-of-care test (TwistDx) for 59 
Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG).  60 
 61 
Methods 62 
Prospective, multi-centre study of symptomatic and asymptomatic patients attending three 63 
English sexual health clinics.  Research samples provided were: additional self-collected 64 
vulvo-vaginal swab (SCVS) (females); first-catch urine (FCU) aliquot (females and males). 65 
Samples were processed blind to the comparator (routine clinic CT/NG Nucleic Acid 66 
Amplification Test (NAAT)) results. Discrepancies were resolved using Cepheid CT/NG 67 
GeneXpert.  68 
 69 
Results 70 
Both RPA and routine clinic NAAT results were available for 392 males and 395 females. CT 71 
positivity was 8.9% (35/392) (male FCU), 7.3% (29/395) (female FCU) and 7.1% (28/395) 72 
(SCVS). Corresponding NG positivity was 3.1% (12/392), 0.8% (3/395) and 0.8% (3/395).    73 
 74 
Specificity and positive predictive values (PPVs) were 100% for all sample types and both 75 
organisms, except male CT FCU (99.7% specificity (95% confidence interval (CI) 98.4-100.0; 76 
356/357), 97.1% PPV (95%CI 84.7-99.9; 33/34)). For CT, sensitivity was ≥94.3% for FCU and 77 
SCVS. CT sensitivity for female FCU was higher (100%, 95%CI 88.1-100; 29/29) than for 78 
SCVS (96.4%, 95%CI 81.7-99.9; 27/28). NG sensitivity and negative predictive values were 79 
100% in FCU (male and female). 80 
 81 
Conclusions 82 
 4 
This prototype test has excellent performance characteristics, comparable to currently-used 83 
NAATs, and fulfils several WHO ASSURED criteria. Its rapidity without loss of performance 84 
suggests that once further developed and commercialised, this test could positively impact 85 
clinical practice and public health. 86 
  87 
 5 
INTRODUCTION 88 
Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are major contributors to the 89 
burden of sexually transmitted infections (STIs) in England and elsewhere [1, 2]. They are 90 
frequently asymptomatic (especially in women) [3], commonly remaining undiagnosed, and if 91 
untreated can lead to serious complications [4, 5].  92 
 93 
Currently, it can take up to two weeks to obtain CT and NG results and treatment after STI 94 
testing in sexual health clinics (SHCs) in the UK [6], but delays may be considerably longer in 95 
other settings [7]. During this period, sexual risk-taking may continue, including acquisition of 96 
new partners [8]. Rapid and accurate CT/NG point-of-care tests (POCTs), enabling diagnosis 97 
and treatment of infected patients within the same clinical visit [9] (a “test-and-treat” strategy), 98 
could potentially reduce rates of inappropriate presumptive treatment, shorten time to 99 
treatment, decrease rates of untreated CT and NG for patients lost to follow-up, limit onward 100 
transmission, and reduce rates of sequelae [10-12].  101 
 102 
British Association for Sexual Health and HIV (BASHH) guidelines state that CT and NG 103 
detection must use nucleic acid amplification tests (NAATs) (and/or culture for NG) [5, 13]. A 104 
number of rapid and POC NAAT-based tests for CT and NG are being, or have recently been, 105 
developed [14]. Newer NAAT technologies that use isothermal amplification, avoiding the 106 
need for thermal cycling, have potential to enable fast turnaround times from sample-to-result. 107 
TwistDx Ltd. (Cambridge, UK) have developed an isothermal Recombinase Polymerase 108 
Amplification (RPA) method, which can detect CT/NG infection (single NG target) in 109 
approximately 15 minutes, requires no thermal cycling, can be battery-powered, and has a 110 
reaction temperature of 37°C. The RPA CT/NG assay is run on the Alere™ i instrument (Alere, 111 
Massachusetts, USA). The TwistDx RPA CT/NG assay is therefore an excellent candidate for 112 
development as a “true” molecular CT/NG POCT, allowing for test-and-treat pathways in 113 
SHCs, community and resource-poor settings [15].   114 
 115 
 6 
We aimed to assess the diagnostic accuracy of the prototype TwistDx RPA assay for genital 116 
CT and NG detection on prospectively collected clinical samples from males and females in 117 
English SHCs.  118 
 119 
METHODS  120 
Ethical approval was granted by the London Bridge Research Ethics Committee (REC 121 
Reference 13/LO/0691). This manuscript was written following Standards for Reporting 122 
Diagnostic Accuracy (STARD) guidelines (see web-only Supplementary Table S1) [16].  123 
 124 
Sample size and recruitment 125 
This prospective multi-centre diagnostic accuracy evaluation was powered to obtain a 126 
minimum of 50 CT and 20 NG positive, and 200 negative, samples for both male and female 127 
participants. Assuming 92% sensitivity and 99% specificity of the RPA CT/NG assay 128 
compared to standard NAATs, the 95% confidence intervals (CIs) obtained would be 81.2-129 
96.8% and 96.4-99.9%, respectively. 130 
 131 
Assuming a CT prevalence of 8.3% (based on Genito-Urinary Medicine Clinical Activity 132 
Dataset (GUMCAD) [17] data from the South London SHC), 600 individuals would lead to the 133 
requisite number of CT positive and negative samples. With a lower expected NG prevalence 134 
of 3%, 800 participants were needed. In order to allow sub-group analysis by gender, we 135 
planned to recruit 400 males and 400 females.  136 
 137 
Study sites and participant selection 138 
Three SHCs located in South London, Yorkshire and on the south coast of England 139 
participated. Eligible patients were recruited during routine consultations by clinic staff using 140 
the following eligibility criteria: aged ≥16 years; attending the SHC; had not passed urine in 141 
the previous two hours; provided written informed consent for the collection of research 142 
samples; provided all sample types (males: first-catch urine (FCU) and meatal swabs pre- and 143 
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post- micturition; females: FCU and self-collected vulvo-vaginal swabs (SCVS)). Participant 144 
demographic and clinical data were collected on case report forms (CRFs). 145 
 146 
Sample collection and processing 147 
All samples for this evaluation were self-taken by participants following collection of routine 148 
clinical samples. A minimum volume of 20 ml male FCU was collected; an aliquot of 2-3 ml 149 
was taken for routine clinical testing, and the remainder immediately stored at 2-8°C until 150 
shipment (twice weekly) on wet ice to TwistDx for RPA CT/NG testing. In addition, male 151 
participants were asked to self-collect two external penile meatal swabs, one pre-urination 152 
and the second post-urination (meatal swab data will be published separately). 153 
 154 
Females provided two SCVS, the first for the clinic’s routine CT/NG NAAT, followed by an 155 
FCU specimen. Female FCU was processed as per male FCU, except that no aliquots for 156 
routine CT/NG NAAT testing were taken. Research SCVS samples were eluted in-clinic within 157 
10 minutes of collection. Swabs were immersed and swirled in 1 ml lysis buffer for 5 seconds, 158 
left to stand (in the lysis buffer) for 90 seconds, and then disposed of. 2 ml neutralisation buffer 159 
was added to the lysis buffer and the tube inverted 10 times. Tubes were stored at -20°C (or 160 
lower) prior to shipment (twice weekly) on dry ice to TwistDx for RPA CT/NG testing.  161 
 162 
Sample testing and resolution of discrepant results 163 
Routine clinical NAAT testing was performed locally on male FCU and female SCVS, as per 164 
clinic standard practice (BD Viper CT/NG assay (Becton Dickinson, Oxford, UK) at the South 165 
London clinic; GenProbe Aptima CT/NG test (Hologic Gen-Probe, Marlborough, USA) at the 166 
other clinics).   167 
  168 
Research sample processing and testing were in accordance with TwistDx protocols, 169 
developed through internal optimisation (unpublished data). The RPA CT/NG assay was 170 
performed on research samples (FCU for men, FCU and SCVS for females) by staff at 171 
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TwistDx, who were blinded to the routine clinic NAAT and CRF results. FCU samples were 172 
processed through a Size Exclusion Chromatography device (Zeta Sep FPLC Desalting 173 
Columns; Generon, Slough, UK) for the purposes of de-salting the sample before testing on 174 
the Alere™ i instrument.  175 
 176 
The comparator test for male FCU samples was the routine clinic NAAT performed on male 177 
FCU; that for female SCVS and FCU was the routine clinic NAAT on female SCVS samples. 178 
Data were sent to the Applied Diagnostic Research & Evaluation Unit (ADREU), St George’s 179 
University of London, where the routine clinic NAAT and RPA CT/NG assay results were 180 
compared for each participant and sample type. We defined the reference standard [16] as 181 
the routine clinic NAAT result when in agreement with the RPA CT/NG assay, and no further 182 
testing was performed. Otherwise, all sample eluates from patients where a discrepant result 183 
had been found were tested at the TwistDx facility using the CT/NG GeneXpert as per 184 
manufacturer’s instructions, blinded to sample type (FCU or swab) and initial CT or NG results. 185 
In these cases, the reference standard was defined as the resolved result when two out of 186 
three of the test results were in agreement.  187 
 188 
Data and statistical analysis 189 
Data were entered into a database by ADREU. Participants for whom either the RPA CT/NG 190 
or routine clinic NAAT results were missing, and/or who did not provide both sample types 191 
(swab and FCU) in the case of females as per the eligibility criteria, were excluded from 192 
analyses. Calculation of RPA CT/NG assay diagnostic accuracy measures (sensitivity, 193 
specificity, positive predictive value (PPV), and negative predictive value (NPV)) and their 194 
binomial exact 95%CIs was carried against the reference standard. Comparison of 195 
performance by sub-group (symptomatic vs. asymptomatic; female FCU vs. SCVS) was 196 
performed using the Pearson chi-squared statistic. All analyses were conducted in Stata v12.0 197 
(StataCorp, Texas, TX, USA). 198 
 199 
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RESULTS 200 
Overview of participants  201 
Recruitment took place May-September 2014. 414 males and 442 females provided written 202 
informed consent (Figures 1 and 2). Both RPA CT/NG assay and routine clinic NAAT results 203 
were available for FCU for 392/414 (94.7%) males. 395/442 (89.7%) females had both FCU 204 
and SCVS results available for all tests performed (RPA CT/NG for FCU and SCVS; routine 205 
clinic NAAT for SCVS). Participant characteristics are summarised in Tables 1A and 1B. Study 206 
CT positivity was 35/392 (8.9%) for male FCU, 29/395 (7.3%) for female FCU and 28/395 207 
(7.1%) for SCVS. Corresponding NG positivities were 12/382 (3.1%), 3/395 (0.8%) and 3/395 208 
(0.8%) (Table 2A).   209 
 210 
CT/NG RPA assay diagnostic accuracy  211 
Table 2 summarises the RPA CT/NG assay diagnostic accuracy estimates (see web-only 212 
Supplementary Table S2 for tables of agreement between the RPA CT/NG assay and 213 
reference standard). In 3/392 (0.8%) FCU samples, RPA CT/NG results disagreed with routine 214 
clinic NAAT results for CT only (there were no NG discrepant results) (see web-only 215 
Supplementary Table S3A). Following discrepant testing, 0/3 (0%) RPA CT/NG results agreed 216 
with the resolved result. Subsequently, in males, all diagnostic accuracy measures were 100% 217 
for NG (12/12, 95%CI 73.5-100 for sensitivity and PPV; 380/380, 95%CI 99.0-100 for 218 
specificity and NPV). For CT, specificity and NPV were ≥99.4% (356/357, 95%CI 98.4-100, 219 
and 356/358, 95%CI 98.0-99.9, respectively), PPV was 97.1% (33/34, 95%CI 84.7-99.9), and 220 
sensitivity was 94.3% (33/35, 95%CI 80.8-99.3) (Table 2A). 221 
 222 
For females, 395 FCU and 395 SCVS were tested for CT and NG by the RPA CT/NG assay  223 
(Table 2A). For CT, 6/790 (0.76%; three FCU, three SCVS) results disagreed with the routine 224 
clinic NAAT SCVS result (see web-only Supplementary Table S3B). Following discrepant 225 
testing, the RPA CT/NG assay agreed with the resolved result for all three FCU discrepants, 226 
and 2/3 SCVS discrepants. For NG, 7/790 (0.89%; three FCU, four SCVS) RPA CT/NG results 227 
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disagreed with the routine clinic NAAT SCVS result (see web-only Supplementary Table S3B). 228 
Of these, all three FCU and 3/4 SCVS discrepants agreed with the resolved result. Thus, in 229 
females, all measures of diagnostic accuracy were 100% for FCU for both CT and NG. For 230 
CT and NG in SCVS, specificity and PPV were 100%, NPV was 99.7% (367/368, 95%CI 98.5-231 
100.0), and sensitivity was 96.4% (27/28, 95%CI 81.7-100) for CT and 66.7% (2/3, 95%CI 232 
9.0-100) for NG (Table 2A). No female had a discrepant result for both CT and NG. 233 
 234 
When performance was analysed by participant-reported symptomatic status, there was no 235 
evidence of a significant difference between symptomatic and asymptomatic patients 236 
(p>0.05). All point estimates were 100% for asymptomatic participants (Table 2C). Among 237 
symptomatic participants (Table 2B), the RPA CT/NG assay’s sensitivity was lower: 15/16 238 
(93.8%, 95%CI 69.8-99.8) for male CT FCU and 13/14 (92.9%, 95%CI 66.1-99.8) for female 239 
CT SCVS, but specificity and NPV remained high. In addition, all diagnostic accuracy 240 
measures for NG detection in both male and female FCU, and female CT FCU detection, were 241 
100% regardless of symptomatic status. (See web-only Supplementary Table S2 for tables of 242 
agreement between the RPA CT/NG assay and reference standard).  243 
 244 
DISCUSSION 245 
In this diagnostic accuracy evaluation of a prototype ultra-rapid isothermal RPA assay for 246 
detection of CT and NG, performance (sensitivity, specificity, PPV and NPV) against the 247 
reference standard for CT was >94% for all sample types evaluated (male FCU; female FCU 248 
and SCVS). Performance for NG was 100% except for SCVS sensitivity and NPV; it was 249 
however not possible to assess NG sensitivity and PPV in females confidently due to low 250 
numbers of positives. The RPA CT/NG also demonstrated excellent technical performance, 251 
as no inhibitory results and very few RPA CT/NG assay device errors were observed.  252 
 253 
With respect to rapidity, the RPA CT/NG assay’s sample preparation, amplification and 254 
detection take place <20 minutes (sample preparation and RPA CT/NG assay run-time). A 255 
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simple-to-use desalting device has been included in newer iterations of the assay, allowing 256 
immediate (in seconds) processing of FCU samples prior to running the assay, although 257 
currently it is only appropriate for research laboratory use. The test’s rapidity enhances the 258 
possibility of implementation as a POCT, enabling “test and treat” strategies with patients 259 
diagnosed and treated in the same clinical visit, and is potentially rapid enough to be 260 
incorporated into clinical practice with minimal change to clinical pathways. To date, a major 261 
barrier identified for STI POCT implementation has been patient willingness to wait, even for 262 
a 90 minute rapid test [11, 18], and the major changes to clinic care pathways necessary to 263 
incorporate rapid tests as POCTs as part of SHC consultations [11, 12]. Consequently, CT/NG 264 
GeneXpert implementation has enabled a same- or next-day results service, rather than a 265 
POCT “test and treat” strategy [19-21]. The RPA CT/NG assay’s rapidity, combined with its 266 
high performance, therefore has the potential to revolutionise STI diagnosis and management. 267 
 268 
Furthermore, the RPA CT/NG assay would be well-suited for use in non-laboratory conditions, 269 
both in low- and high-income countries, due to its limited operational requirements. In 270 
resource-limited settings, laboratory services for STIs are either not available, or are difficult 271 
to access (physically and/or financially), and the development and introduction of affordable 272 
STI POCTs are part of the World Health Organization (WHO)’s strategic direction [22]. The 273 
RPA CT/NG assay fulfils many of the ASSURED criteria, developed by WHO as a benchmark 274 
to decide if tests address disease control needs in developing countries [23], and could 275 
therefore be an excellent candidate for a true CT/NG POCT in multiple settings.  276 
 277 
BASHH guidelines for NG testing indicate a minimum PPV of 90%; below this, positives should 278 
be confirmed with supplementary testing using a different nucleic acid target from the original 279 
test [5]. Although our NG PPV point estimates were all 100%, the lower 95%CI were all <90%. 280 
As the RPA CT/NG assay has only a single NG molecular target, it may ultimately have lower 281 
specificity and PPV compared to two-target assays, especially if applied to lower prevalence 282 
settings. That said, a diagnostic evaluation with large sample size of the two-target GeneXpert 283 
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by Gaydos et al. [24] also resulted in NG PPVs with lower 95%CIs <90% in all sample types 284 
despite the point estimate being >90%, indicating that supplementary testing may be required 285 
for both assay types in low prevalence settings. 286 
 287 
The RPA CT/NG assay shows promise for both screening of asymptomatics and diagnosis of 288 
symptomatics, as we found no significant difference in point estimates by symptomatic status, 289 
in accordance with previously reported findings [24]. Furthermore, both SCVS and FCU are 290 
possible sample types for females. This is interesting, as it has previously been reported that 291 
urine is less sensitive than swabs, probably because of lower bacterial load [25]; we did not 292 
have data on organism load to explore this finding further. It is also possible that different 293 
sample storage (extracted SCVS eluate frozen versus FCU refrigerated prior to testing) could 294 
have contributed to this finding. Freeze-thaw is unlikely to have impacted on results (one 295 
freeze-thaw for FCU prior to discrepant testing; maximum two freeze-thaws for SCVS (the first 296 
for initial testing and the second for discrepant testing)), particularly as CT DNA detection by 297 
PCR is unaffected by extended (≤2 years) storage [26]. Our results must however be 298 
interpreted with caution, as it would have been more appropriate to compare the RPA CT/NG 299 
assay FCU results to clinic FCU NAAT results, had these been available, but female FCU is 300 
not routinely collected in England. Due to the very high performance of the assay in this 301 
evaluation, it is expected that use of the clinic FCU NAAT as the gold standard would have 302 
made very little difference.   303 
 304 
It is known that the discrepant analysis approach employed in this study can lead to biases, 305 
particularly when the assay under evaluation is also part of the algorithm used to define true 306 
positive and negative results [27]. However, agreement between the initial clinic NAAT and 307 
RPA CT/NG assay was very high, with few samples requiring discrepant resolution. Logistical 308 
and funding constraints meant an alternative study design (for example, composite gold 309 
standard or Patient Infection Status (PIS) as used for FDA approval [27]), with a consistent 310 
definition for all sample types, was not possible.   311 
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 312 
The results of our evaluation are promising for the further development of the RPA CT/NG 313 
assay, the aims of which should be to: (a) increase CT sensitivity; (b) ensure the PPV remains 314 
>90%; c) ensure usability; (d) and perform larger evaluations to achieve tighter confidence 315 
intervals around point estimates, especially for NG. An important addition to this test’s 316 
development would be validation of extra-genital (pharyngeal and rectal) sample types. Extra-317 
genital samples are routinely collected for MSM, with the majority of NG infections in MSM 318 
detected extra-genitally [28].  319 
 320 
This prototype RPA CT/NG assay has excellent performance characteristics, comparable to 321 
currently-used NAATs, and fulfils several WHO ASSURED criteria, most notably accuracy, 322 
rapidity, and thermo-stability. Its rapidity without loss of performance suggests that once 323 
further developed and commercialised, this test could positively impact on both clinical 324 
practice and public health. 325 
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TABLES AND FIGURES 449 
 450 
Fig. 1. Patient and sample flow for male participants 451 
Fig. 2. Patient and sample flow for female participants 452 
 453 
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Table 1. Participant characteristics 
 Male participants Female participants 
Characteristic No. of 
participants 
(%) 
CT NG No. of 
participants 
(%) 
CT NG 
No. 
(%) 
with 
CTa 
No. (%) 
with NGa 
No. (%) 
with CTa 
No. (%) 
with NGa 
Age       
16-19 15 
(3.8) 
1 
(6.7) 
0 
(0) 
40 
(10.1) 
5 
(12.5) 
0 
(0) 
20-24 126 
(32.1) 
22 
(17.5) 
6 
(4.8) 
157 
(39.7) 
18 
(11.5) 
0 
(0) 
25-34 148 
(37.8) 
11 
(7.4) 
2 
(1.4) 
140 
(35.4) 
4 
(2.9) 
1 
(0.7) 
35-44 64 
(16.3) 
0 
(0) 
3 
(4.7) 
41  
(10.4) 
1 
(2.4) 
1 
(2.4) 
45-64 37 
(9.4) 
1 
(2.7) 
1 
(2.7) 
16  
(4.1) 
0 
(0) 
0 
(0) 
65+ 2 
(0.5) 
0 
(0) 
0 
(0) 
1  
(0.3) 
0 
(0) 
0 
(0) 
Clinic       
1 127 
(32.4) 
13 
(10.2) 
7 
(5.5) 
157  
(39.7) 
8  
(5.1) 
2 
(1.3) 
 20 
2 186 
(47.4) 
18 
(9.7) 
4 
(2.2) 
161  
(40.8) 
16  
(9.9) 
1 
(0.6) 
3 79 
(20.2) 
4 
(5.1) 
1 
(1.3) 
77  
(19.5) 
4  
(5.2) 
0 
(0) 
Contact       
No 340 
(87.4) 
18 
(5.3) 
10 
(2.9) 
363  
(92.8) 
16  
(4.4) 
2 
(0.6) 
CT only 33 
(8.5) 
14 
(42.4) 
2 
(6.1) 
22  
(5.6) 
11  
(50.0) 
0 
(0) 
NG only 7 
(1.8) 
2 
(28.6) 
0 
(0) 
1  
(0.3) 
0  
(0) 
1 
(100) 
Both CT & 
NG 
9 
(2.3) 
1 
(11.1) 
0 
(0) 
5  
(1.3) 
0  
(0) 
0 
(0) 
Taken CT/NG 
active 
medication 
since test/6 
weeks before 
test 
      
No 375 
(95.7) 
34 
(9.1) 
11 
(2.9) 
367  
(92.9) 
27  
(7.4) 
3 
(0.8) 
Yes 17 
(4.3) 
1 
(5.9) 
1 
(5.9) 
28  
(7.1) 
1  
(3.6) 
0 
(0) 
 21 
Symptomaticb       
No 249 
(63.7) 
18 
(7.2) 
2 
(0.8) 
208  
(52.8) 
14  
(6.7) 
1 
(0.5) 
Yes 142 
(36.3) 
16 
(11.3) 
10 
(7.0) 
186  
(47.2) 
14  
(7.5) 
2 
(1.1) 
Currently 
menstruating 
      
No N/A N/A N/A 368  
(93.4) 
28  
(7.6) 
3 
(0.8) 
Yes N/A N/A N/A 26  
(6.6) 
0  
(0) 
0 
(0) 
a CT and NG positives defined as reference standard (positive by at least 2 of the 3 tests: 454 
clinic NAAT, RPA CT/NG assay, Cepheid GeneXpert). 455 
b Male participants considered symptomatic if they reported ≥1 of the following symptoms on 456 
the Case Report Form: Discharge (clear or cloudy liquid from the penis); Irritation at the top 457 
of the penis; Itching; Needing to pass urine more often than usual; Pain/burning when 458 
urinating. Female participants considered symptomatic if they reported ≥1 of the following 459 
symptoms on the Case Report Form: Itching; Discharge(clear or cloudy liquid from the 460 
vagina); Pain/burning when urinating; Needing to pass urine more frequently; Pain during 461 
sex; Bleeding after sex; Bleeding in between periods; Pelvic abdominal pain. 462 
 463 
 464 
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Table 2. RPA CT/NG assay performance 
A: All participants 
 Males Females 
 FCU FCU SCVS 
 CT NG CT NG CT NG 
No. positivesa / total 35/392 12/392 29/395 3/395 28/395 3/395 
Positivity 8.9% 3.1% 7.3% 0.8% 7.1% 0.8% 
Sensitivity (%, 95%CI) 
n/N 
94.3 (80.8-99.3) 
33/35 
100 (73.5-100) 
12/12 
100 (88.1-100) 
29/29 
100 (29.2-100) 
3/3 
96.4 (81.7-99.9) 
27/28 
66.7 (9.0-100) 
2/3 
Specificity (%, 95%CI) 
n/N 
99.7 (98.4-100) 
356/357 
100 (99.0-100) 
380/380 
100 (99.0-100) 
366/366 
100 (99.1-100) 
392/392 
100 (99.0-100) 
367/367 
100 (99.1-100) 
392/392 
PPV (%, 95%CI) 
n/N 
97.1 (84.7-99.9) 
33/34 
100 (73.5-100) 
12/12 
100 (88.1-100) 
29/29 
100 (29.2-100) 
3/3 
100 (87.2-100) 
27/27 
100 (15.8-100) 
2/2 
NPV (%, 95%CI) 99.4 (98.0-99.9) 100 (99.0-100) 100 (99.0-100) 100 (99.1-100) 99.7 (98.5-100) 99.7 (98.6-100) 
 23 
n/N 356/358 380/380 366/366 392/392 367/368 392/393 
B: Symptomatic participantsb 
 Males Females 
 FCU FCU SCVS 
 CT NG CT NG CT NG 
No. positivesa / total 16/142 10/142 14/186 2/186 14/186 2/186 
Positivity 11.3% 7.0% 7.5% 1.1% 7.5% 1.1% 
Sensitivity (%, 95%CI) 
n/N 
93.8 (69.8-99.8) 
15/16 
100 (69.2-100) 
10/10 
100 (76.8-100) 
14/14 
100 (15.8-100) 
2/2 
92.9 (66.1-99.8) 
13/14 
50 (1.3-98.7) 
1/2 
Specificity (%, 95%CI) 
n/N 
99.2 (95.7-100) 
125/126 
100 (97.2-100) 
132/132 
100 (97.9-100) 
172/172 
100 (98.0-100) 
184/184 
100 (97.9-100) 
172/172 
100 (98.0-100) 
184/184 
PPV (%, 95%CI) 
n/N 
93.8 (69.8-99.8) 
15/16 
100 (69.2-100) 
10/10 
100 (76.8-100) 
14/14 
100 (15.8-100) 
2/2 
100 (75.3-100) 
13/13 
100 (2.5-100) 
1/1 
NPV (%, 95%CI) 99.2 (95.7-100) 100 (97.2-100) 100 (97.9-100) 100 (98.0-100) 99.4 (96.8-100) 99.5 (97.0-100) 
 24 
n/N 125/126 132/132 172/172 184/184 172/173 184/185 
C: Asymptomatic participants 
 Males Females 
 FCU FCU SCVS 
 CT NG CT NG CT NG 
No. positivesa / total 18/249 2/249 15/208 1/208 14/208 1/208 
Positivity 7.2% 0.8% 7.2% 0.48% 6.7% 0.48% 
Sensitivity (%, 95%CI) 
n/N 
100 (81.5-100) 
18/18 
100 (15.8-100) 
2/2 
100 (78.2-100) 
15/15 
100 (2.5-100) 
1/1 
100 (76.8-100) 
14/14 
100 (2.5-100) 
1/1 
Specificity (%, 95%CI) 
n/N 
100 (98.4-100) 
231/231 
100 (98.5-100) 
247/247 
100 (98.1-100) 
193/193 
100 (98.2-100) 
207/207 
100 (98.1-100) 
194/194 
100 (98.2-100) 
207/207 
PPV (%, 95%CI) 
n/N 
100 (81.5-100) 
18/18 
100 (15.8-100) 
2/2 
100 (78.2-100) 
15/15 
100 (2.5-100) 
1/1 
100 (76.8-100) 
14/14 
100 (2.5-100) 
1/1 
NPV (%, 95%CI) 100 (98.4-100) 100 (98.5-100) 100 (98.1-100) 100 (98.2-100) 100 (98.1-100) 100 (98.2-100) 
 25 
n/N 231/231 247/247 193/193 207/207 194/194 207/207 
 465 
FCU, First-catch urine; SCVS, Self-Collected Vulvo-Vaginal Swab; CT, Chlamydia trachomatis; NG, Neisseria gonorrhoeae; PPV, Positive 466 
Predictive Value; NPV, Negative Predictive Value 467 
a Positives defined as reference standard (positive by at least 2 of the 3 tests: clinic NAAT, RPA CT/NG assay, Cepheid GeneXpert) 468 
b Male participants considered symptomatic if they reported ≥1 of the following symptoms on the Case Report Form: Discharge (clear or cloudy 469 
liquid from the penis); Irritation at the top of the penis; Itching; Needing to pass urine more often than usual; Pain/burning when urinating. 470 
Female participants considered symptomatic if they reported ≥1 of the following symptoms on the Case Report Form: Itching; Discharge(clear 471 
or cloudy liquid from the vagina); Pain/burning when urinating; Needing to pass urine more frequently; Pain during sex; Bleeding after sex; 472 
Bleeding in between periods; Pelvic abdominal pain  473 
 474 
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